Introduction Statins, inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, are the most extensively applied cholesterol-reducing medicine to prevent cardiovascular events (Downs et al., 1998)
As clinical trials accumulate evidence and regulatory bodies move toward harmonized standards, peptide-based therapies will likely become more widely available, complementing established stem cell programs rather than competing with them
This analytical review aims to critically examine the current evidence surrounding GLP-1 agonists for obesity treatment in non-diabetic patients, evaluating their therapeutic potential against existing limitations and challenges
Rebates are a valuable tool for negotiating price concessions from manufacturers when there are multiple competing products
GABA is a naturally occurring neurotransmitter that reduces the activity of overactive neurons (brain cells) promoting a sense of calm and contentment
Genetic Factors in GLP-1 Response and Recovery The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761) variants that relate to GLP-1 and related signaling pathways